TELA Bio Inc. (TELA)
TELA Bio Statistics
Share Statistics
TELA Bio has 39.39M shares outstanding. The number of shares has increased by 59.79% in one year.
Shares Outstanding | 39.39M |
Shares Change (YoY) | 59.79% |
Shares Change (QoQ) | 59.38% |
Owned by Institutions (%) | 72.91% |
Shares Floating | 31.65M |
Failed to Deliver (FTD) Shares | 400 |
FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 351.56K, so 0.89% of the outstanding shares have been sold short.
Short Interest | 351.56K |
Short % of Shares Out | 0.89% |
Short % of Float | 1.14% |
Short Ratio (days to cover) | 1.97 |
Valuation Ratios
The PE ratio is -3.24 and the forward PE ratio is -4.21. TELA Bio's PEG ratio is 0.13.
PE Ratio | -3.24 |
Forward PE | -4.21 |
PS Ratio | 2.59 |
Forward PS | 0.5 |
PB Ratio | 8.02 |
P/FCF Ratio | -3.65 |
PEG Ratio | 0.13 |
Enterprise Valuation
TELA Bio Inc. has an Enterprise Value (EV) of 147.44M.
EV / Earnings | -3.16 |
EV / Sales | 2.52 |
EV / EBITDA | -3.63 |
EV / EBIT | -3.35 |
EV / FCF | -3.56 |
Financial Position
The company has a current ratio of 4.23, with a Debt / Equity ratio of 2.18.
Current Ratio | 4.23 |
Quick Ratio | 3.45 |
Debt / Equity | 2.18 |
Total Debt / Capitalization | 68.51 |
Cash Flow / Debt | -0.99 |
Interest Coverage | -8.44 |
Financial Efficiency
Return on equity (ROE) is -2.47% and return on capital (ROIC) is -73.51%.
Return on Equity (ROE) | -2.47% |
Return on Assets (ROA) | -0.6% |
Return on Capital (ROIC) | -73.51% |
Revenue Per Employee | $257,502.2 |
Profits Per Employee | $-205,568.28 |
Employee Count | 227 |
Asset Turnover | 0.75 |
Inventory Turnover | 1.39 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.14% in the last 52 weeks. The beta is 1.1, so TELA Bio's price volatility has been higher than the market average.
Beta | 1.1 |
52-Week Price Change | -66.14% |
50-Day Moving Average | 2.73 |
200-Day Moving Average | 3.48 |
Relative Strength Index (RSI) | 31.9 |
Average Volume (20 Days) | 170.72K |
Income Statement
In the last 12 months, TELA Bio had revenue of 58.45M and earned -46.66M in profits. Earnings per share was -2.04.
Revenue | 58.45M |
Gross Profit | 40.11M |
Operating Income | -44.08M |
Net Income | -46.66M |
EBITDA | -40.63M |
EBIT | -44.08M |
Earnings Per Share (EPS) | -2.04 |
Balance Sheet
The company has 46.73M in cash and 41.08M in debt, giving a net cash position of 5.65M.
Cash & Cash Equivalents | 46.73M |
Total Debt | 41.08M |
Net Cash | 5.65M |
Retained Earnings | -320.89M |
Total Assets | 53.02M |
Working Capital | 27.27M |
Cash Flow
In the last 12 months, operating cash flow was -40.86M and capital expenditures -611K, giving a free cash flow of -41.47M.
Operating Cash Flow | -40.86M |
Capital Expenditures | -611K |
Free Cash Flow | -41.47M |
FCF Per Share | -1.81 |
Margins
Gross margin is 68.62%, with operating and profit margins of -75.4% and -79.83%.
Gross Margin | 68.62% |
Operating Margin | -75.4% |
Pretax Margin | -79.83% |
Profit Margin | -79.83% |
EBITDA Margin | -69.51% |
EBIT Margin | -75.4% |
FCF Margin | -70.94% |
Dividends & Yields
TELA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -86.81% |
FCF Yield | -44.9% |
Analyst Forecast
The average price target for TELA is $10, which is 325.5% higher than the current price. The consensus rating is "Buy".
Price Target | $10 |
Price Target Difference | 325.5% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Scores
Altman Z-Score | -8.55 |
Piotroski F-Score | 1 |